$44.00
-0.09 (-0.20%)
QURE News4 articles
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
UniQure Holds Gains as FDA Signals Path for Huntington's Gene Therapy Filing
UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.
FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy
uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.
uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.